早产儿视网膜病变:单中心筛查与治疗进展
该回顾性队列研究分析了1990至2019年间某三级NICU中7436例接受ROP筛查的早产儿,发现ROP发病率随三十年下降(P < .05),但极早产儿(BW <750 g)比例上升且病变更重、更需治疗(P < .05);进展至4、5期的比例下降,玻璃体腔注射贝伐珠单抗作为初始和挽救治疗的使用增加。
要点
- 三十年ROP总体发病率下降(P < .05),但极早产儿比例上升且病变更重。
- 极早产儿(BW <750 g)病变分区、分期、plus病及治疗需求均增加(P < .05)。
- 进展至4、5期比例下降,玻璃体腔注射贝伐珠单抗使用增加。
核心结论
- ROP总体发病率随三十年下降(P < .05),但极早产儿比例上升且病变更重、更需治疗(P < .05)。
- 进展至4、5期的比例下降,玻璃体腔注射贝伐珠单抗作为初始和挽救治疗的使用增加。
- 极早产是治疗必要性ROP的重要危险因素,随新生儿护理改善而持续增加。
研究设计与样本
- 回顾性队列研究,纳入1990至2019年某三级NICU中出生胎龄<32周或出生体重1500 g的连续早产儿。
主要发现
- 共纳入7436例患儿,完成25567次检查。
- 三十年间ROP发病率下降(P < .05)。
- 平均出生体重和胎龄上升,但ROP患儿出生体重和胎龄随时间降低(P < .05)。
- 极早产儿(BW <750 g)比例持续上升,其病变分区、分期、plus病及治疗需求增加(P < .05)。
- 进展至4、5期的比例下降,玻璃体腔注射贝伐珠单抗作为初始和挽救治疗的使用增加。
关键数值与推荐
- 筛查纳入标准:出生胎龄<32周或出生体重1500 g。
- 极早产定义:出生体重<750 g。
临床怎么用
- 关注极早产儿(BW <750 g)这一高风险群体,其病变更重且更需治疗。
- 玻璃体腔注射贝伐珠单抗可作为初始和挽救治疗选择,与进展至4、5期比例下降相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To focus on the longitudinal evaluation of high-risk infants for the development of retinopathy of prematurity (ROP) at a single tertiary neonatal intensive care unit (NICU), and to evaluate evolving demographics of ROP and the transition of treatment-warranted disease. DESIGN: Retrospective cohort study. METHODS: A consecutive retrospective review was performed of all infants screened for ROP between 1990 and 2019 at the Jackson Memorial Hospital neonatal intensive care unit. All inborn infants meeting a birth criteria of <32 weeks' gestational age (GA) or a birthweight (BW) of 1500 g were included. Longitudinal demographic, diagnostic, and treatment data were reported. RESULTS: Between January 1, 1990, and June 20, 2019, a total of 25,567 examinations were performed and 7436 patients were included. Longitudinal trends over 3 decades demonstrated a decreasing incidence of ROP (P < .05). Although the mean BW and GA increased over 3 decades, patients with ROP demonstrated lower BW and GA over time (P < .05). The prevalence of micro-premature infants (as defined by BW <750 g) continues to rise over time. Micro-preemies demonstrated increasing severity of zone and stage grading, plus disease, and propensity to require treatment (P < .05). The rate of progression of ROP to stage 4 and 5 disease has decreased over time, and there has been an associated increased adoption of intravitreal bevacizumab as primary and salvage therapy. CONCLUSIONS: Understanding the evolution of ROP infants and treatment over time is critical in identifying high-risk infants and in reducing the incidence of severe-stage ROP. Micro-prematurity is one of the significant risk factors for treatment-warranted ROP that continues to increase as neonatal care improves. NOTE: Publication of this article is sponsored by the American Ophthalmological Society.
引用
- Berrocal AM, Fan KC, Al-Khersan H, et al. Retinopathy of Prematurity: Advances in the Screening and Treatment of Retinopathy of Prematurity Using a Single Center Approach. Am J Ophthalmol. 2021. PMID: 34298009. doi:10.1016/j.ajo.2021.07.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。